Phase II Trial Assessing the Feasibility and Toxicity of Degarelix in Achieving Prostate Downsizing Prior to Treatment With Permanent Seed Prostate Brachytherapy
All men will have a baseline transrectal ultrasound for brachytherapy planning that has
demonstrated an enlarged prostate with or without pubic arch obstruction. After signing the
informed consent document they will have a loading dose of 240 mg Degarelix and then monthly
maintenance dose injections of 80 mg until such time as sufficient prostate reduction has
occured (2-3 months) or they complete the 6 months of required androgen ablation for their
disease status.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
prostate volume reduction
determined by transrectal ultrasound with planimetry volume calculation
3 months
No
Juanita M Crook, MD
Principal Investigator
British Columbia Cancer Agency
Canada: Institutional Review Board
H11-08172
NCT01446991
April 2012
October 2014
Name | Location |
---|